Presented July News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The use of skin-lightening products is associated with a wide range of complications. Is squamous cell carcinoma one of them?

Results of the 30-month data cut of the 3-year GALE open-label extension trial of pegcetacoplan for geographic atrophy showed that the drug produced clinically meaningful reductions in lesion growth.

An extension study found no cases of occlusive retinal vasculitis after 23,000 injections of pegcetacoplan, but a panel received more reports of the complication and dealt with conflicts of interest.

Patients taking glucagon-like peptide-1 agonists were more likely to progress from nonproliferative diabetic retinopathy to proliferative disease or diabetic macular edema than those who took sodium-glucose cotransporter-2 inhibitors.

Recalled in 2022, a port delivery system for ranibizumab to treat wet AMD demonstrated that vision and retinal anatomy remained stable in patients who had the device for 5 years.